Abcodia | GenomeWeb

Abcodia

Opening next year with funds from the UK's Medical Research Council, the center will have roughly 12 new mass specs for discovery and targeted proteomics.

In the UK it initially will be offered through private clinics on a "self-pay" basis, while in the US it will be sold as a laboratory-developed test through Abcodia's CLIA lab.

The company plans to launch the test, which uses serial CA-125 measurements, in the UK this summer and in the US later this year.

Caprion will use its discovery and targeted mass spec platforms to analyze roughly 400 samples from the UK Collaborative Trial for Ovarian Cancer Screening.

Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.

NEW YORK (GenomeWeb) – OncoCyte and Abcodia today announced they will collaborate on the development of OncoCyte's gene expression-based diagnostic test for the early detection of breast cancer.

NEW YORK (GenomeWeb News) – Life Technologies said this week that it has opened up a 'Customer Experience Centre' in Russia in collaboration with one of its distributors, Khimexpert.

A longitudinal study of the Risk of Ovarian Cancer Algorithm has found that the algorithm in combination with transvaginal ultrasound offers suitable specificity and positive predictive value for it to be used as an ovarian cancer screening test in post-menopausal women.

NEW YORK (GenomeWeb News) – UK cancer biomarker firm Abcodia today announced a collaboration with the Austrian Institute of Technology to validate biomarkers for the early detection of lung and colorectal cancers.

NEW YORK (GenomeWeb News) – Cancer Research UK's commercial arm, Cancer Research Technology (CRT), will partner with the biomarker validation firm Abcodia to develop blood tests for detecting early-stage cancers, CRUK said today.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.